Relay Therapeutics Inc. stocks have been trading up by 12.81 percent after promising clinical trial news boosted investor optimism.
Live Update At 11:32:51 EDT: On Tuesday, May 19, 2026 Relay Therapeutics Inc. stock [NASDAQ: RLAY] is trending up by 12.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RLAY has been grinding higher on the chart even as the company posts deep red numbers. Over the last few weeks, Relay Therapeutics stock has climbed from the low $12s to around $13.65, with several sharp intraday swings that active traders love. The daily candles show repeated dips toward $11.60–$12.00 getting bought, a sign that dip buyers are defending that zone.
Intraday on the latest session, RLAY whipsawed from a premarket spike above $14 down to $11.63 at the open, then clawed back to the mid-$13s. That kind of range shows aggressive trading on both sides but ends with momentum leaning higher.
Fundamentally, Relay Therapeutics is still a classic clinical-stage biotech: $3.0M in quarterly revenue against a net loss of about $73.3M and an EBITDA loss near $72.8M. Margins are massively negative, and there is no meaningful price-to-earnings ratio yet. But RLAY sits on roughly $204.6M in cash, with a huge current ratio above 22 and minimal debt. For traders, that balance sheet says the company can fund its pipeline for a while, even as the income statement bleeds. The story here is not earnings; it is data, catalysts, and sentiment.
Why Traders Are Watching RLAY’s Bullish Pipeline Story
Relay Therapeutics is giving traders exactly what drives big moves in biotech: clean clinical data and a visible catalyst path. The centerpiece is zovegalisib, the company’s PI3Kα inhibitor. In Phase 1/2, RLAY reported a 44% objective response rate when zovegalisib was combined with Pfizer’s CDK4 inhibitor atirmociclib and endocrine therapy in heavily pretreated HR+/HER2- metastatic breast cancer. For traders, that number is huge. This isn’t an easy setting; these patients have already seen a lot of therapy.
On top of the response rate, the safety profile stands out. Analysts highlighted good tolerability and, crucially, Oppenheimer called out the absence of Grade 3 hyperglycemia, a common headache with other PI3K inhibitors. That safety angle gives Relay Therapeutics a potential edge if it holds up in larger Phase 3 trials.
Wall Street has noticed. Goldman Sachs blasted its price target on RLAY from $13 to $22. H.C. Wainwright went even further, hiking from $19 to $25 and saying the triplet data de-risks the upcoming Phase 3. Oppenheimer moved to $18, while Wells Fargo lifted to $21 and started modeling a first-line opportunity, even as it waits to see durability versus competing PI3K inhibitors. Citizens nudged its target to $19, stressing the competitive advantage of the Pfizer-linked atirmociclib component in endocrine-sensitive frontline settings.
All this is anchored by a clear plan: Relay Therapeutics is advancing zovegalisib plus atirmociclib and endocrine therapy into a frontline Phase 3 trial for PI3Kα‑mutated HR+/HER2- disease, backed by a Pfizer supply agreement, around early 2027. At the same time, RLAY continues a separate Phase 3 in second-line disease and explores vascular anomaly indications. For momentum traders, that is a pipeline with multiple shots on goal and a steady catalyst calendar.
More Breaking News
- AUR Stock Consolidates After Sharp Multi-Week Run
- POET Technologies Slides As Legal And Dilution Risks Mount
- WNW Stock Whipsaws As Insider Ownership Filing Hits Tape
- RGTI Stock Pulls Back As Quantum Hype Cools
Conclusion
Under the hood, Relay Therapeutics is still burning cash fast. Quarterly operating cash flow was about -$51.1M, and free cash flow matched that loss. R&D ran roughly $70.6M for the quarter, reinforcing that RLAY is in heavy spend mode to push zovegalisib and its broader pipeline, including the NRAS-selective oncology candidate RLY-8161. The Q1 report also showed a wider-than-expected loss and a revenue miss, which would normally pressure a stock like this.
Yet the market’s focus is firmly on Relay Therapeutics’ future, not its current profits. With more than $204M in cash, low debt, and strong working capital, the balance sheet buys RLAY time to chase value in breast cancer and vascular anomalies. The Pfizer partnership around atirmociclib and the transition of zovegalisib into Phase 3 frontline and second-line trials give traders clearly defined moments where sentiment can shift again.
For active traders who live on volatility, RLAY offers a textbook biotech setup: strong analyst upgrades, a data-driven bull story, and big swings on the chart. As Tim Sykes likes to say, “The market doesn’t care about your opinion, it cares about catalysts and price action — learn to spot both, and you give yourself a real edge.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. That reminder can be crucial for traders navigating fast-moving names like RLAY, where hype and sharp price spikes can tempt undisciplined chasing. Relay Therapeutics is now firmly on that catalyst map. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply